Portal de Periódicos da CAPES

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

2023; Elsevier BV; Volume: 165; Issue: 6 Linguagem: Inglês

10.1053/j.gastro.2023.08.038

1528-0012

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Brian Bressler, Matthew Germinaro, Kuan-Hsiang Gary Huang, Nicole Shipitofsky, Hongyan Zhang, Rebbecca Wilson, Chenglong Han, Brian G. Feagan, William J. Sandborn, Julián Panés, Tadakazu Hisamatsu, Gary R. Lichtenstein, Bruce E. Sands, Axel Dignaß, О. Аbrahamovych, Halyna Afanasieva, Lilia Aitova, Engin Altıntaş, Romain Altwegg, П. С. Андреев, Kazuki Aomatsu, Monika Augustyn, Paola Balestrieri, Jakob Begun, Luciana Brunatto, Diego Bulgheroni, Elena Bunkova, Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Baili Chen, Chou‐Chen Chen, Chou-Pin Chen, Cheng‐Tang Chiu, Chang Hwan Choi, Michele Cicala, Olena Datsenko, Pieter Dewint, Eugeni Domènech, Joris Dutré, George Duvall, J. C. Fernández, Rafał Filip, Ronald Fogel, Sharyle Fowler, Toshimitsu Fujii, Masayuki Fukata, Yohei Furumoto, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Cyrielle Gilletta, Paolo Gionchetti, Eran Goldin, Oleksandr Golovchenko, Maciej Gonciarz, Can Gönen, Gaston Gonzalez Segura, Oleksii Gridnyev, T Gyökeres, Xavier Hébuterne, Charlotte Hedin, Per M. Hellström, Ida Hilmi, Ivo Horný, Gyula Horvat, Namiko Hoshi, Luděk Hrdlička, Shunji Ishihara, Olha Ivanishyn, Byung Ik Jang, Odery Ramos, Takashi Kagaya, Shuji Kanmura, Marina Karakina, Nakai Katsuhiko, Jarosław Kierkuś, Hyo Jong Kim, Tae Oh Kim, Young‐Ho Kim, G Kiss, Jochen Klaus, D Kleczkowski, Maria Kłopocka, Taku Kobayashi, Iwona Kobielusz-Gembala, Ja Seol Koo, Adam Kopoń, Tetiana Kravchenko, Masatoshi Kudo, Kwang An Kwon, Paula Lago, David Laharie, Ian C. Lawrance, Jarosław Leszczyszyn, Yan Li, Milan Lukáš, Christian Maaser, Atsuo Maemoto, Hiroyuki Marusawa, Matthew J. McBride, Shoba Mendu, Pál Miheller, Hideharu Miyabayashi, W Mohl, Gregory Moore, Satoshi Motoya, Narayanachar Murali, Mohammed Al Naem, Koichi Nakajima, Yasunari Nakamoto, Stéphane Nancey, Joaquim Isquierdo Quadrado Neto, Michio Onizawa, Yohei Ono, Yohei Ono, Taro Osada, М. Ф. Осипенко, Danuta Owczarek, Bhaktasharan Patel, Kamal Patel, Elina Petrova, Е Г Порошина, Francisco Portela, Lyudmyla Prystupa, Montserrat Rivero, Xavier Roblin, J Romatowski, Grażyna Rydzewska, Simone Saibeni, Hirotake Sakuraba, Mark Samaan, Michael Schultz, J Schulze, Shahriar Sedghi, Ursula Seidler, Sung Jae Shin, Mykola Stanislavchuk, David Stokesberry, Takayoshi Suzuki, Hiroki Taguchi, Lyudmila Tankova, Lena Thin, Tkachev Av, Leyanira Torrealba, Nataliia Tsarynna, Zsolt Tulassay, Tetsuya Ueo, Ekaterina Valuyskikh, Olga Vasilevskaya, Manuel Viamonte, Shu‐Chen Wei, Roni Weisshof, Katarzyna Wójcik‐Pszczoła, Byong Duk Ye, Hsu–Heng Yen, Hyuk Yoon, Kosuke Yoshida, Andriy Yurkiv, Osamu Zaha, Qiang Zhan,

Dermatology and Skin Diseases

The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.